Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prediabetes or Diabetes Clear all

Conditions: Prediabetes or Overweight
Interventions: Whole food fiber mixture, inulin; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, PreDiabetes, Hypertension, High Blood Pressure, High Blood Sugar, Obesity, Overweight, Overweight and Obesity, Overweight or Obesity
Interventions: The Diabetes Prevention Program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: grape seed polyphenolic extract, resveratrol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Blood Glucose, Blood Insulin
Interventions: Acute beverage (water) consumption, Acute beverage (Black Coffee) consumption, Acute beverage (Orange Juice) consumption, Acute beverage (Whole Milk) consumption, Acute beverage (2% Milk) consumption, Acute beverage (Skim Milk) consumption; Other
Lead sponsor: Purdue University; Other
Eligibility: 35 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Autism Spectrum Disorder (ASD), Cardiometabolic Health Indicators, Cardiometabolic Risk Factors, Metabolic Syndrome, Prediabetes
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Gestational Diabetes Mellitus in Pregnancy, Glucose Intolerance During Pregnancy, Non-nutritive Sweeteners Consumption in Pregnancy and/or Lactation
Interventions: NNS Restriction Intervention, Control Intervention; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Prediabetes
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: PreDiabetes, Cardiovascular Diseases
Interventions: Individualized Nutrition Therapy; Other
Lead sponsor: George Mason University; Other
Eligibility: 45 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions: Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone; Procedure · Radiation · Drug
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Pre-diabetes
Interventions: Control, Xenin-25 without atropine, GIP without atropine, Placebo with atropine, Xenin-25 with atropine, GIP with atropine, GIP plus Xenin-25 without atropine, GIP plus Xenin-25 with atropine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Congestive Heart Failure
Interventions: Avandia (Rosiglitazone), Avanclia (Rosiqlitazone); Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Diabetes, Pre-diabetes
Interventions: Weight loss and exercise training intervention, Weight loss Only Intervention; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes, Heart Failure
Interventions: Metformin; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 90 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Overweight and Obesity, Pre Diabetes
Interventions: TREAT pilot intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 45 Years to 73 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Pre-diabetes, Type 2 Diabetes
Interventions: Exenatide, Sitagliptin, Glimepiride; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Type II Diabetes Mellitus
Interventions: Spice polyphenols; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 35 Years to 70 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity, Overweight
Interventions: Tirzepatide, Semaglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 30
States / cities: Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 24 more

Conditions: Cystic Fibrosis Related Diabetes
Interventions: Insulin Pump, Insulin, Oral Glucose Tolerance Test, Whole body Protein Turnover; Device · Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 32 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Elevated Body Mass Index
Interventions: LIK066, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Type 2 Diabetes, Prediabetes
Interventions: Mindfulness Based Group; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 2 Diabetes, HbA1c, Protein Intake
Interventions: PP; Dietary Supplement
Lead sponsor: Skidmore College; Other
Eligibility: 30 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Saratoga Springs, New York

Conditions: Prediabetes
Interventions: Stelo CGM; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Overweight or Obesity, Prediabetes or Diabetes, Prehypertension (Elevated Blood Pressure) or Hypertension, Resistance Training
Interventions: Resistance Training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 30 Years to 64 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 80
States / cities: Anniston, Alabama • Birmingham, Alabama • Pelham, Alabama + 73 more

Search by objective public record fields.

Whole Food Fibers for Support of Key Gut Bacteria for Human Health

A Virtual Cardiometabolic Health Program for African Immigrants: The Afro-DPP Program

BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)

Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults

This Study Will Evaluate Cardiorespiratory and Muscular Fitness to Examine Associations With Anthropometric Characteristics and Other Indicators of Cardiometabolic Risk Among Patients With or Without Autism Spectrum Disorder

Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes

Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo

Individualized Nutrition Therapy for Preventing or Delaying Onset of Type-2 Diabetes

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion

Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity

A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)

Time Restricted EATing (TREAT) Pilot Study

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.

Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

A Mindfulness-based Intervention for Adolescents With Prediabetes or Type 2 Diabetes

Daily Protein Pacing Effects on HbA1c in Type 2 Diabetics

Trial of CGM Technology in Persons Living With Prediabetes

Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity